摘要
目的探讨普瑞巴林联合巴氯芬治疗三叉神经痛的效果与安全性。方法选取2021年1月至2023年6月郑州卷烟厂康复医院收治的三叉神经痛患者104例,依据治疗方案不同分为对照组和观察组,每组52例。对照组用巴氯芬治疗,观察组用普瑞巴林联合巴氯芬治疗。分析两组临床治疗有效率、疼痛程度、生活质量、炎症因子、氧化应激指标及不良反应。结果观察组治疗总有效率92.31%高于对照组76.92%,差异有统计学意义(P<0.05);治疗后,观察组VAS评分低于对照组,生活质量评分高于对照组(P<0.05);观察组血清IL-1β、IL-6、TNF-α水平低于对照组(P<0.05);观察组血清SOD、GSH-Px水平升高,MDA水平降低(P<0.05);两组不良反应比较,差异无统计学意义(P>0.05)。结论普瑞巴林联合巴氯芬治疗三叉神经痛,可减轻疼痛程度,抑制炎症反应与氧化应激反应,提高治疗效果。
Objective To investigate the efficacy and safety of pregabalin combined with baclofen in the treatment of trigeminal neuralgia.Methods 104 trigeminal neuralgia patients admitted to the Rehabilitation Hospital of Zhengzhou Cigarette Factory from January 2021 to June 2023 were selected and divided into the control group and observation group according to different treatment plans,with 52 cases in each group.The control group were treated with baclofen,and the observation group were treated with pregabalin combined with baclofen.The clinical treatment efficiency,pain degree,quality of life,inflammatory factor oxidative stress indicator agent adverse reactions were analyzed between two groups.Results The total effective rate of the observation group was 92.31%,which was higher than 76.92%of the control group,and the difference was statistically significant(P<0.05).After treatment,the VAS score of the observation group was lower than that of the control group,and the quality of life score was higher than that of the control group(P<0.05).The serum levels of IL-1β,IL-6,and TNF-αin the observation group were lower than those in the control group(P<0.05).The levels of SOD and GSH-Px in the observation group increased,while the level of MDA decreased(P<0.05).There was no statistically significant difference in adverse reactions between the two groups(P>0.05).Conclusion Pregabalin combined with baclofen treatment of trigeminal neuralgia improves the therapeutic effect,reduces pain levels,inhibits inflammation-oxidative stress reactions,and has certain safety.
作者
王海洋
孟凡超
张丽霞
WANG Haiyang;MENG Fanchao;ZHANG Lixia(Department of Neurological Rehabilitation,Zhengzhou Cigarette Factory Rehabilitation Hospital,Zhengzhou 450000,China;Department of Neurology,Zhengzhou Second People′s Hospital,Zhengzhou 450000,China)
出处
《华夏医学》
CAS
2024年第5期120-124,共5页
Acta Medicinae Sinica
基金
河南省医学科技攻关联合共建项目(LHGJ20206617)。
